C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression

Guillermina A. Melendi, Scott J. Hoffman, Ruth A Karron, Pablo M. Irusta, Federico R. Laham, Alison Humbles, Brian Schofield, Chien Hsiung Pan, Richard Rabold, Bhagvanji Thumar, Adeep Thumar, Norma P. Gerard, Wayne A Mitzner, Scott R. Barnum, Craig Gerard, Steven R. Kleeberger, Fernando P. Polack

Research output: Contribution to journalArticle

Abstract

Enhanced respiratory syncytial virus disease, a serious pulmonary disorder that affected recipients of an inactivated vaccine against respiratory syncytial virus in the 1960s, has delayed the development of vaccines against the virus. The enhanced disease was characterized by immune complex-mediated airway hyperreactivity and a severe pneumonia associated with pulmonary eosinophilia. In this paper, we show that complement factors contribute to enhanced-disease phenotypes. Mice with a targeted disruption of complement component C5 affected by the enhanced disease displayed enhanced airway reactivity, lung eosinophilia, and mucus production compared to wild-type mice and C5-deficient mice reconstituted with C5. C3aR expression in bronchial epithelial and smooth muscle cells in the lungs of C5-deficient mice was enhanced compared to that in wild-type and reconstituted rodents. Treatment of C5-deficient mice with a C3aR antagonist significantly attenuated airway reactivity, eosinophilia, and mucus production. These results indicate that C5 plays a crucial role in modulating the enhanced-disease phenotype, by affecting expression of C3aR in the lungs. These findings reveal a novel autoregulatory mechanism for the complement cascade that affects the innate and adaptive immune responses.

Original languageEnglish (US)
Pages (from-to)991-999
Number of pages9
JournalJournal of Virology
Volume81
Issue number2
DOIs
StatePublished - Jan 2007

Fingerprint

Pulmonary Eosinophilia
eosinophilia
Respiratory Syncytial Viruses
Virus Diseases
lungs
viruses
receptors
mice
Lung
complement
Eosinophilia
Mucus
mucus
Complement C5
Phenotype
phenotype
Inactivated Vaccines
antigen-antibody complex
inactivated vaccines
vaccine development

ASJC Scopus subject areas

  • Immunology

Cite this

C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. / Melendi, Guillermina A.; Hoffman, Scott J.; Karron, Ruth A; Irusta, Pablo M.; Laham, Federico R.; Humbles, Alison; Schofield, Brian; Pan, Chien Hsiung; Rabold, Richard; Thumar, Bhagvanji; Thumar, Adeep; Gerard, Norma P.; Mitzner, Wayne A; Barnum, Scott R.; Gerard, Craig; Kleeberger, Steven R.; Polack, Fernando P.

In: Journal of Virology, Vol. 81, No. 2, 01.2007, p. 991-999.

Research output: Contribution to journalArticle

Melendi, GA, Hoffman, SJ, Karron, RA, Irusta, PM, Laham, FR, Humbles, A, Schofield, B, Pan, CH, Rabold, R, Thumar, B, Thumar, A, Gerard, NP, Mitzner, WA, Barnum, SR, Gerard, C, Kleeberger, SR & Polack, FP 2007, 'C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression', Journal of Virology, vol. 81, no. 2, pp. 991-999. https://doi.org/10.1128/JVI.01783-06
Melendi, Guillermina A. ; Hoffman, Scott J. ; Karron, Ruth A ; Irusta, Pablo M. ; Laham, Federico R. ; Humbles, Alison ; Schofield, Brian ; Pan, Chien Hsiung ; Rabold, Richard ; Thumar, Bhagvanji ; Thumar, Adeep ; Gerard, Norma P. ; Mitzner, Wayne A ; Barnum, Scott R. ; Gerard, Craig ; Kleeberger, Steven R. ; Polack, Fernando P. / C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. In: Journal of Virology. 2007 ; Vol. 81, No. 2. pp. 991-999.
@article{d4ff45da0fd74a5f81ebd4100b871431,
title = "C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression",
abstract = "Enhanced respiratory syncytial virus disease, a serious pulmonary disorder that affected recipients of an inactivated vaccine against respiratory syncytial virus in the 1960s, has delayed the development of vaccines against the virus. The enhanced disease was characterized by immune complex-mediated airway hyperreactivity and a severe pneumonia associated with pulmonary eosinophilia. In this paper, we show that complement factors contribute to enhanced-disease phenotypes. Mice with a targeted disruption of complement component C5 affected by the enhanced disease displayed enhanced airway reactivity, lung eosinophilia, and mucus production compared to wild-type mice and C5-deficient mice reconstituted with C5. C3aR expression in bronchial epithelial and smooth muscle cells in the lungs of C5-deficient mice was enhanced compared to that in wild-type and reconstituted rodents. Treatment of C5-deficient mice with a C3aR antagonist significantly attenuated airway reactivity, eosinophilia, and mucus production. These results indicate that C5 plays a crucial role in modulating the enhanced-disease phenotype, by affecting expression of C3aR in the lungs. These findings reveal a novel autoregulatory mechanism for the complement cascade that affects the innate and adaptive immune responses.",
author = "Melendi, {Guillermina A.} and Hoffman, {Scott J.} and Karron, {Ruth A} and Irusta, {Pablo M.} and Laham, {Federico R.} and Alison Humbles and Brian Schofield and Pan, {Chien Hsiung} and Richard Rabold and Bhagvanji Thumar and Adeep Thumar and Gerard, {Norma P.} and Mitzner, {Wayne A} and Barnum, {Scott R.} and Craig Gerard and Kleeberger, {Steven R.} and Polack, {Fernando P.}",
year = "2007",
month = "1",
doi = "10.1128/JVI.01783-06",
language = "English (US)",
volume = "81",
pages = "991--999",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression

AU - Melendi, Guillermina A.

AU - Hoffman, Scott J.

AU - Karron, Ruth A

AU - Irusta, Pablo M.

AU - Laham, Federico R.

AU - Humbles, Alison

AU - Schofield, Brian

AU - Pan, Chien Hsiung

AU - Rabold, Richard

AU - Thumar, Bhagvanji

AU - Thumar, Adeep

AU - Gerard, Norma P.

AU - Mitzner, Wayne A

AU - Barnum, Scott R.

AU - Gerard, Craig

AU - Kleeberger, Steven R.

AU - Polack, Fernando P.

PY - 2007/1

Y1 - 2007/1

N2 - Enhanced respiratory syncytial virus disease, a serious pulmonary disorder that affected recipients of an inactivated vaccine against respiratory syncytial virus in the 1960s, has delayed the development of vaccines against the virus. The enhanced disease was characterized by immune complex-mediated airway hyperreactivity and a severe pneumonia associated with pulmonary eosinophilia. In this paper, we show that complement factors contribute to enhanced-disease phenotypes. Mice with a targeted disruption of complement component C5 affected by the enhanced disease displayed enhanced airway reactivity, lung eosinophilia, and mucus production compared to wild-type mice and C5-deficient mice reconstituted with C5. C3aR expression in bronchial epithelial and smooth muscle cells in the lungs of C5-deficient mice was enhanced compared to that in wild-type and reconstituted rodents. Treatment of C5-deficient mice with a C3aR antagonist significantly attenuated airway reactivity, eosinophilia, and mucus production. These results indicate that C5 plays a crucial role in modulating the enhanced-disease phenotype, by affecting expression of C3aR in the lungs. These findings reveal a novel autoregulatory mechanism for the complement cascade that affects the innate and adaptive immune responses.

AB - Enhanced respiratory syncytial virus disease, a serious pulmonary disorder that affected recipients of an inactivated vaccine against respiratory syncytial virus in the 1960s, has delayed the development of vaccines against the virus. The enhanced disease was characterized by immune complex-mediated airway hyperreactivity and a severe pneumonia associated with pulmonary eosinophilia. In this paper, we show that complement factors contribute to enhanced-disease phenotypes. Mice with a targeted disruption of complement component C5 affected by the enhanced disease displayed enhanced airway reactivity, lung eosinophilia, and mucus production compared to wild-type mice and C5-deficient mice reconstituted with C5. C3aR expression in bronchial epithelial and smooth muscle cells in the lungs of C5-deficient mice was enhanced compared to that in wild-type and reconstituted rodents. Treatment of C5-deficient mice with a C3aR antagonist significantly attenuated airway reactivity, eosinophilia, and mucus production. These results indicate that C5 plays a crucial role in modulating the enhanced-disease phenotype, by affecting expression of C3aR in the lungs. These findings reveal a novel autoregulatory mechanism for the complement cascade that affects the innate and adaptive immune responses.

UR - http://www.scopus.com/inward/record.url?scp=33846059798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846059798&partnerID=8YFLogxK

U2 - 10.1128/JVI.01783-06

DO - 10.1128/JVI.01783-06

M3 - Article

C2 - 17079327

AN - SCOPUS:33846059798

VL - 81

SP - 991

EP - 999

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 2

ER -